Semax: A Nootropic Research Peptide Derived from ACTH

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4-7), extended with the same Pro-Gly-Pro stabilising tripeptide used in the structurally related peptide Selank. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences — the same laboratory responsible for Selank — Semax has been the subject of extensive preclinical research spanning cognitive function, neurotrophic factor expression, and neuroprotective mechanisms in animal models. Unlike full-length ACTH, Semax does not stimulate adrenal steroidogenesis, making it a distinct research tool for studying the non-endocrine effects of melanocortin-derived peptide fragments. This overview examines the structural design, published mechanistic research, and current investigational directions associated with this ACTH-derived nootropic peptide.

Origins: From ACTH to a Nootropic Research Fragment

The intellectual origins of Semax trace to research conducted in the 1970s and 1980s on the behavioural effects of ACTH fragments in animal models. Pioneering work by researchers including de Wied and van Wimersma Greidanus demonstrated that short fragments of ACTH — particularly the ACTH(4-10) sequence — could influence learning and memory parameters in rodent behavioural paradigms without stimulating adrenal cortisol production. This dissociation between the endocrine and behavioural effects of ACTH fragments represented a significant finding in peptide neuroscience.

ACTH itself is a 39-amino-acid peptide derived from the precursor protein pro-opiomelanocortin (POMC) through post-translational proteolytic processing. The ACTH(4-10) fragment (Met-Glu-His-Phe-Arg-Trp-Gly) retains activity at melanocortin receptors but lacks the N-terminal ACTH(1-3) sequence critical for adrenal stimulation. The observation that even shorter fragments — ACTH(4-7): Met-Glu-His-Phe — retained some behavioural activity in preclinical assays prompted efforts to develop stabilised analogues of this minimal active sequence.

Myasoedov and colleagues at the Institute of Molecular Genetics selected the ACTH(4-7) tetrapeptide as the core pharmacophore and appended the Pro-Gly-Pro tripeptide — the same C-terminal extension used to stabilise Selank. The resulting heptapeptide, Semax, demonstrated enhanced enzymatic stability while preserving the neurobehavioural activity observed with the parent ACTH fragments.

Structure and the Pro-Gly-Pro Stabilisation Strategy

Semax's amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro, with a molecular weight of approximately 813.9 Da. The design parallels Selank's in using the Pro-Gly-Pro motif to confer resistance to amino- and carboxypeptidase degradation.

The Met-Glu-His-Phe core represents the minimum ACTH fragment that retains activity in published behavioural assays. Notably, this sequence differs from the full ACTH(4-10) fragment (Met-Glu-His-Phe-Arg-Trp-Gly) by truncating the Arg-Trp-Gly C-terminal portion and replacing it with Pro-Gly-Pro. This design choice reflects a trade-off between maximising the minimal pharmacophore and optimising stability — the Pro-Gly-Pro extension provides greater proteolytic resistance than the native C-terminal residues.

An important structural consideration is the methionine residue at position 1. Methionine's thioether side chain is susceptible to oxidation under non-ideal storage conditions, which can compromise peptide integrity. Proper storage and handling protocols — including protection from oxidative conditions — are therefore particularly relevant for Semax preparations.

Mechanism Research: Neurotrophic Factors and Signalling Pathways

Published mechanistic research on Semax has identified several signalling pathways and molecular targets:

BDNF and NGF Expression

Paralleling the findings reported for Selank, published research has documented that Semax influences the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in rodent brain tissue. Studies examining mRNA levels in the hippocampus and cortex have reported upregulation of both neurotrophins following Semax administration in animal models. Dolotov et al. published data demonstrating that Semax increased BDNF mRNA expression in the rat hippocampus and basal forebrain regions — areas critical for memory and cognitive function in rodent models.

The neurotrophic factor connection is one of the most frequently cited mechanisms in the Semax literature, as BDNF and NGF are established mediators of synaptic plasticity, neuronal survival, and neuritogenesis in preclinical research.

Gene Expression Profiling

Broad gene expression analyses — similar to those conducted for Selank — have been published for Semax. Research by Filippenkov et al. examined transcriptomic changes in rat brain tissue following Semax administration, reporting differential expression of genes involved in neurotransmitter signalling, inflammatory responses, and intracellular signalling cascades. These transcriptomic datasets indicate that Semax's molecular effects extend well beyond a single receptor target.

Melanocortin Receptor Research

Given its structural derivation from ACTH, researchers have investigated Semax's interactions with the melanocortin receptor (MCR) family — a group of five GPCRs (MC1R–MC5R) that mediate the diverse effects of POMC-derived peptides. Published binding studies suggest that Semax and the ACTH(4-7) fragment have relatively low affinity for classical melanocortin receptor binding sites compared to alpha-MSH or full-length ACTH. This has led some researchers to propose that Semax's neurobehavioural effects may be mediated through non-classical receptor targets or signalling mechanisms that are not fully captured by standard MCR binding assays.

Cognitive Research in Animal Models

Semax has been studied across multiple standard cognitive and behavioural paradigms in preclinical research:

Passive avoidance: Multiple published studies have examined Semax in the passive avoidance paradigm — a fear-conditioned learning task. Published data report enhanced retention of the conditioned response in Semax-administered rodents compared to controls, with effects observed across multiple rodent strains and administration protocols.

Morris water maze: Spatial learning research using the Morris water maze has been published for Semax, with some studies reporting improved acquisition of the spatial task in rodent models. These findings are consistent with the documented effects on hippocampal BDNF expression.

Novel object recognition: Research using the novel object recognition task — which assesses recognition memory — has also been conducted with Semax in rodent models. Published data contribute to a broader cognitive research profile spanning multiple memory domains.

Active avoidance: Some research groups have examined Semax in active avoidance paradigms, where the animal must learn to perform a specific action to avoid an aversive stimulus. Published results add to the behavioural evidence base, though the strength and consistency of effects across studies varies by paradigm and protocol.

All behavioural findings should be interpreted within the strict context of the animal models used.

Neuroprotective Research in Preclinical Models

A significant body of published Semax research involves neuroprotection — the study of mechanisms that protect neuronal viability under conditions of stress or damage in experimental models:

Ischemia models: Researchers have examined Semax in animal models of cerebral ischemia (reduced blood flow to brain tissue). Published studies have reported changes in infarct volume, neuronal survival markers, and functional outcomes in rodent ischemia models following Semax administration. These studies are purely preclinical and involve standardised surgical ischemia protocols (such as middle cerebral artery occlusion, MCAO).

Oxidative stress models: In vitro studies have examined Semax's effects on neuronal cell cultures subjected to oxidative challenge. Published data report changes in cell viability parameters, reactive oxygen species levels, and expression of antioxidant genes in Semax-exposed cultures.

Inflammatory signalling: Published transcriptomic analyses have identified changes in inflammatory gene expression profiles following Semax administration in animal models of neuronal stress, suggesting that modulation of neuroinflammatory signalling may be a component of the peptide's observed neuroprotective effects in these models.

Handling and Research Considerations

Researchers working with Semax should note the following practical considerations:

Current Research Directions and Comparative Studies

Several active areas of Semax research merit attention:

Semax vs Selank: Given that both peptides were developed at the same institute using the same Pro-Gly-Pro stabilisation strategy, comparative research examining their distinct and overlapping effects is an active area. Our Selank vs Semax comparison examines this topic in detail.

Modified Semax analogues: Published research has explored modified versions of Semax, including adamantylated forms (Semax-adamantane, also known as Adamax) and other N-terminal modifications, designed to further enhance stability or alter receptor interaction profiles. These second-generation analogues represent an ongoing effort to refine the structure-activity relationship of ACTH-derived nootropic peptides.

Transcriptomic integration: As gene expression datasets from Semax studies accumulate, researchers are applying bioinformatic approaches to integrate these data and identify core signalling networks affected by the peptide. Network analysis and pathway enrichment tools allow researchers to move beyond individual gene changes toward systems-level understanding of Semax's molecular effects.

The published Semax literature represents one of the more extensive bodies of preclinical peptide nootropic research available. For researchers investigating neurotrophic signalling, cognitive paradigms, or ACTH-derived peptide pharmacology, this compound provides a well-characterised research tool with a substantial foundation of published data.

---

For research use only. Not for human consumption. The information provided is for educational and research purposes only. Products referenced are not intended to diagnose, treat, cure, or prevent any disease. Always consult published peer-reviewed literature before designing research protocols.